{"id":"warfarin-accordingly-inr-value","safety":{"commonSideEffects":[{"rate":"1–3% per year (major bleeding)","effect":"Bleeding (major and minor)"},{"rate":"<1%","effect":"Warfarin-induced skin necrosis"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1464","moleculeType":"Small molecule","molecularWeight":"308.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin acts as a vitamin K antagonist, blocking the synthesis of vitamin K-dependent coagulation factors in the liver. The INR is monitored to ensure therapeutic anticoagulation (typically 2–3 for most indications) while minimizing bleeding risk. Dosing is adjusted based on INR values to maintain the target range.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) to reduce thrombus formation and is dosed according to INR (International Normalized Ratio) monitoring.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:08.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (DVT/PE) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT02705976","phase":"NA","title":"Prospective Trial of a Validated Algorithm for Warfarin Dosing","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2014-09","conditions":"Anticoagulation","enrollment":211},{"nctId":"NCT00623987","phase":"PHASE4","title":"Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico","startDate":"1999-06","conditions":"Deep Vein Thrombosis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["warfarin"],"phase":"marketed","status":"active","brandName":"warfarin accordingly INR value","genericName":"warfarin accordingly INR value","companyName":"Azienda Ospedaliera Universitaria Policlinico","companyId":"azienda-ospedaliera-universitaria-policlinico","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin is a small molecule used for anticoagulation and the treatment of deep vein thrombosis, with its dosage adjusted according to the International Normalized Ratio (INR) value. The INR value is a measure used to monitor the effectiveness of warfarin therapy and ensure it is within a safe and therapeutic range.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}